Latest Administration News

Minbos Resources has appointed Rob Newbold as Acting CEO following the resignation of Lindsay Reed, while grappling with administrative and shareholder challenges delaying its key phosphate project in Angola.

GQG Partners delivered solid full-year 2025 results, with funds under management climbing 7.1% to US$163.9 billion and net income increasing 7.3% to US$463.3 million, despite net outflows. The firm maintained a strong dividend payout, reflecting confidence in its sustainable growth strategy.

BWP Group has reported a 3% rise in revenue to $103.6 million for the half-year ending December 2025, driven by rental growth and strategic acquisitions. The internalisation of management has reduced fees and positioned the group for future growth.

ADX Energy has restarted flow testing at its Welchau-1 well in Austria after regulatory delays, aiming to confirm the commercial viability of light oil and gas-condensate reservoirs in the Reifling Formation.

AMP Limited reported a robust FY25 with underlying NPAT up 20.8%, driven by strong cashflow growth, cost reductions, and new product launches including AMP Bank GO and AMP Lifetime Pension. The company sets a steady course for FY26 with continued focus on retirement solutions and AI-driven innovation.

Entropy Neurodynamics has been granted an Australian patent for its novel two-phase IV infusion method administering psilocybin and psilocin, securing exclusive rights through 2042 and strengthening its lead asset TRP-8803’s competitive position.

Santos Limited reports a stable 2025 reserves position with a 17-year life and significant growth in CO2 storage capacity, underpinning its decarbonisation strategy. The company also provides preliminary guidance on its 2025 financial results.

Argenica Therapeutics has reported a significant increase in its half-year loss to $3.82 million, driven by reduced revenue and higher research and development expenses. The company continues to invest heavily in its neuroprotective drug candidate ARG-007 amid ongoing clinical trials.

Island Pharmaceuticals has confirmed the material significance of recent FDA feedback on its Galidesivir development pathway and addressed ASX queries on disclosure timing and capital raising activities.

Brightstar Resources has launched a $5 million Share Purchase Plan offering eligible shareholders discounted shares to fund key mining projects. The offer opens on 10 February and closes on 27 February 2026.

Regal Partners Global Investments Limited has updated its Dividend Reinvestment Plan to reflect its recent rebranding and remove participation barriers, effective immediately for the 1H26 interim dividend.

American Uranium Limited has upgraded its U.S. trading status to the OTCQB Venture Market, enhancing liquidity and accessibility for North American investors. This move supports the company’s strategy to expand its U.S. shareholder base and increase visibility for its flagship uranium project in Wyoming.